Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
The diagnosis and treatment of prostate cancer: a review
Importance Prostate cancer is the most common cancer diagnosis made in men with more
than 160 000 new cases each year in the United States. Although it often has an indolent …
than 160 000 new cases each year in the United States. Although it often has an indolent …
Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review
L Moris, MG Cumberbatch, T Van den Broeck… - European urology, 2020 - Elsevier
Context The optimal treatment for men with high-risk localized or locally advanced prostate
cancer (PCa) remains unknown. Objective To perform a systematic review of the existing …
cancer (PCa) remains unknown. Objective To perform a systematic review of the existing …
Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management
JA Eastham, GB Auffenberg, DA Barocas… - The Journal of …, 2022 - auajournals.org
Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …
Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial
LGW Kerkmeijer, VH Groen, FJ Pos… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE This study investigates whether focal boosting of the macroscopic visible tumor
with external beam radiotherapy increases biochemical disease-free survival (bDFS) in …
with external beam radiotherapy increases biochemical disease-free survival (bDFS) in …
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 …
D Dearnaley, I Syndikus, H Mossop, V Khoo… - The Lancet …, 2016 - thelancet.com
Background Prostate cancer might have high radiation-fraction sensitivity that would give a
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …
therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of …
[HTML][HTML] COVID-19: Global radiation oncology's targeted response for pandemic preparedness
As the global COVID-19 pandemic escalates there is a need within radiation oncology to
work to support our patients in the best way possible. Measures are required to reduce …
work to support our patients in the best way possible. Measures are required to reduce …
Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer
CN Catton, H Lukka, CS Gu, JM Martin… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Men with localized prostate cancer often are treated with external radiotherapy (RT)
over 8 to 9 weeks. Hypofractionated RT is given over a shorter time with larger doses per …
over 8 to 9 weeks. Hypofractionated RT is given over a shorter time with larger doses per …
Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a …
WJ Morris, S Tyldesley, S Rodda, R Halperin… - International Journal of …, 2017 - Elsevier
Purpose To report the primary endpoint of biochemical progression-free survival (b-PFS)
and secondary survival endpoints from ASCENDE-RT, a randomized trial comparing 2 …
and secondary survival endpoints from ASCENDE-RT, a randomized trial comparing 2 …
Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer
Purpose Conventional radiotherapy (C-RT) treatment schedules for patients with prostate
cancer typically require 40 to 45 treatments that take place from> 8 to 9 weeks. Preclinical …
cancer typically require 40 to 45 treatments that take place from> 8 to 9 weeks. Preclinical …
Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial
JM Michalski, J Moughan, J Purdy, W Bosch… - JAMA …, 2018 - jamanetwork.com
Importance Optimizing radiation therapy techniques for localized prostate cancer can affect
patient outcomes. Dose escalation improves biochemical control, but no prior trials were …
patient outcomes. Dose escalation improves biochemical control, but no prior trials were …